HAL (France)open access
The BEVATOMOX phase II trial: raltitrexed/oxaliplatin/bevacizumab vs mFOLFOX6/bevacizumab in 2nd-line metastatic colorectal cancer
0, Bevacizumab, 1, Metastatic colorectal cancer, Oxaliplatine, Raltitrexed, Second line treatment
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Record · ID 311896
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.